Delgocitinib

Chemical compound
  • D11AH11 (WHO)
Legal statusLegal status
  • Rx-only in Japan
Identifiers
  • 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number
  • 1263774-59-9
PubChem CID
  • 50914062
DrugBank
  • DB16133
ChemSpider
  • 59718502
UNII
  • 9L0Q8KK220
KEGG
  • D11046
CompTox Dashboard (EPA)
  • DTXSID401336933 Edit this at Wikidata
Chemical and physical dataFormulaC16H18N6OMolar mass310.361 g·mol−13D model (JSmol)
  • Interactive image
  • C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
InChI
  • InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
  • Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.[2]

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.[3]

References

  1. ^ a b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.
  2. ^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
  3. ^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.
  • v
  • t
  • e